Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Steris (STEResearch Report) and Mirati Therapeutics (MRTXResearch Report) with bullish sentiments.

Steris (STE)

JMP Securities analyst David Turkaly reiterated a Buy rating on Steris today and set a price target of $250.00. The company’s shares closed last Wednesday at $160.98, close to its 52-week low of $159.21.

According to TipRanks.com, Turkaly is a 2-star analyst with an average return of -0.1% and a 40.6% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Steris with a $250.00 average price target.

See the top stocks recommended by analysts >>

Mirati Therapeutics (MRTX)

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Mirati Therapeutics, with a price target of $110.00. The company’s shares closed last Wednesday at $61.94.

According to TipRanks.com, Tuerkcan is a 3-star analyst with an average return of 2.8% and a 31.6% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Taysha Gene Therapies, and Logicbio Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirati Therapeutics with a $101.00 average price target, implying a 59.7% upside from current levels. In a report issued on November 4, BMO Capital also maintained a Buy rating on the stock with a $110.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on STE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More